SHAREHOLDER ALERT: WeissLaw LLP Investigates Millendo Therapeutics, Inc.

NEW YORK, April 27, 2021 /PRNewswire/ --

If you own Millendo shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:

http://www.weisslawllp.com/MLND/

Or please contact:
Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16^th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Millendo Therapeutics, Inc. ("Millendo" or the "Company") MLND in connection with the proposed merger of the Company with privately-held clinical-stage oncology company Tempest Therapeutics, Inc. ("Tempest").  Under the terms of the merger agreement, the two companies will combine their businesses in an all-stock transaction that will result in one combined entity that will trade publicly on the Nasdaq Capital Market.  At close of the transaction, Tempest shareholders are expected to own 81.5% of the newly-combined company, with Millendo stockholders owning only approximately 18.5%. 

WeissLaw LLP is investigating whether Millendo's board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, whether the board was fully informed as to the valuation of the combined company, whether the deal's equity split is fair to Millendo stockholders, and whether all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com

SOURCE WeissLaw LLP